Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on Novo Nordisk’s early lead in the obesity market.

Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2024, the FDA gave a thumbs-up to more than xx new treatments, which was down from 60-plus new drugs in 2023.

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates and other assets in the final few days of 2024.

Drugmakers plan to raise U.S. list prices on some 250 branded drugs beginning this month, Reuters reports, citing data from healthcare research firm 3 Axis Advisors. Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi.

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate asset to its pipeline.

Currax Pharmaceuticals is kicking off the new year with a new direct-to-consumer campaign for its weight loss medication Contrave.

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage readouts on Neumora’s lead drug candidate has ended in failure, wiping more than 80% off the value of the biotech.

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.